elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Empagliflozin
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Empagliflozin
RIS
0.001
(Research Intensity Score)
Papers
121
Top papers
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
2020 · 5146 citations
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
2020 · 891 citations
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
2024 · 118 citations
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
2024 · 94 citations
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 · 12282 citations
Newest papers
Empagliflozin mitigated cisplatin induced renal endothelial dysfunction in rats via repressing oxidative, inflammatory, apoptotic and fibrotic signals
2026 · 1 citations
Empagliflozin enhances cisplatin activity in chemo-resistant EJ138 bladder cancer cells: The importance of anti-diabetic medications in cancer treatment
2026 · 1 citations
SGLT2 inhibitors and secondary polycythemia: a systematic review and meta-analysis of hematologic effects in patients with type 2 diabetes
2026
Adoption and diffusion of SGLT2 inhibitors among cardiologists in medicare part D, 2019–2023: a provider-level observational study
2026
Analysis of Allele-Specific Expression Highlights Novel Participants of Empagliflozin-Driven Effects on T2DM-Associated Regulatory Pathways
2026
A sample from the 100 top papers behind Empagliflozin.
Create a free account to browse them all →
Empagliflozin's history
Research intensity over time
Explore Empagliflozin's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Empagliflozin's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link